California State Teachers Retirement System lowered its stake in shares of Inogen Inc (NASDAQ:INGN) by 9.7% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 27,273 shares of the medical technology company’s stock after selling 2,914 shares during the period. California State Teachers Retirement System owned approximately 0.13% of Inogen worth $2,594,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Schroder Investment Management Group acquired a new position in shares of Inogen during the second quarter valued at about $132,000. Ameritas Investment Partners Inc. raised its position in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares in the last quarter. Victory Capital Management Inc. raised its position in Inogen by 17.8% in the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after purchasing an additional 307 shares in the last quarter. Pinebridge Investments L.P. raised its position in Inogen by 1.6% in the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after purchasing an additional 33 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Inogen in the third quarter worth about $213,000.
Inogen Inc (NASDAQ:INGN) opened at $115.59 on Friday. Inogen Inc has a 52-week low of $62.69 and a 52-week high of $130.05. The stock has a market cap of $2,403.64, a PE ratio of 93.98, a P/E/G ratio of 3.90 and a beta of 1.13.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. During the same quarter in the prior year, the business posted $0.25 earnings per share. The company’s quarterly revenue was up 26.8% compared to the same quarter last year. equities research analysts anticipate that Inogen Inc will post 1.19 earnings per share for the current fiscal year.
Several research analysts recently issued reports on INGN shares. Needham & Company LLC increased their price target on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. Leerink Swann reissued an “outperform” rating and issued a $120.00 price target (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a research report on Thursday, November 9th. Finally, BidaskClub lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $102.71.
In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $94.07, for a total transaction of $1,316,980.00. Following the sale, the director now directly owns 7,808 shares of the company’s stock, valued at $734,498.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at $119,060. The disclosure for this sale can be found here. Insiders have sold 81,500 shares of company stock worth $9,267,695 over the last ninety days. Insiders own 5.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.truebluetribune.com/2018/01/14/inogen-inc-ingn-shares-sold-by-california-state-teachers-retirement-system.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.